Can-Fite BioPharma Ltd.
CANF · Pharmaceutical Preparations · EDGAR filings ↗
Grade
D43Can-Fite is a deeply loss-making clinical-stage biopharma with only ~2.5 quarters of cash runway despite multiple Phase III programs.
Strengths
- Multiple late-stage assets (Piclidenoson, Namodenoson) with numerous out-licensing partnerships
- Current ratio 3.5 and Fast Track/orphan designations for Namodenoson
Risks
- Cash runway ~2.5 quarters (21.8th pct); deeply negative margins and ROE (-176%)
- Revenue down ~40%, chronic operating losses, NYSE American listing/dilution risk, Israel geopolitical exposure
Notable findings
- Net lossNet loss (net margin -2426.7%)
- Cash burnNegative free cash flow (-9.0M)
- Revenue declineRevenue -39.9% YoY
- Notable holderHeld by 1 notable fund(s): CITADEL ADVISORS LLC (as of 2026-03-31)
Key metrics
Operating margin
-2456.8%
Net margin
-2426.7%
Return on equity
-175.8%
Return on assets
-103.3%
Revenue growth (QoQ)
-39.9%
Current ratio
3.5×
Free cash flow
-$9M
EBITDA
-$10M
Tangible book value
$6M
Cash & investments
$6M
Cash runway
2q
Stock comp / revenue
84.0%
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-26 | 2025-12-31 | 0001213900-26-034447 ↗ |
| 20-F | 2025-04-14 | 2024-12-31 | 0001213900-25-031298 ↗ |
| 20-F | 2024-03-28 | 2023-12-31 | 0001213900-24-026947 ↗ |
| 20-F | 2023-03-30 | 2022-12-31 | 0001213900-23-024298 ↗ |
| 20-F | 2022-03-24 | 2021-12-31 | 0001213900-22-014672 ↗ |
| 20-F | 2021-03-25 | 2020-12-31 | 0001213900-21-017630 ↗ |
| 20-F | 2020-03-27 | 2019-12-31 | 0001213900-20-007682 ↗ |
| 20-F | 2019-03-29 | 2018-12-31 | 0001213900-19-005251 ↗ |
| 20-F | 2018-03-28 | 2017-12-31 | 0001213900-18-003554 ↗ |
| 20-F | 2017-03-30 | 2016-12-31 | 0001213900-17-003022 ↗ |
| 20-F | 2016-03-31 | 2015-12-31 | 0001213900-16-012161 ↗ |
| 20-F | 2015-03-27 | 2014-12-31 | 0001213900-15-002133 ↗ |